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Abstract Genetic mutations that severely diminish the
activity of aspartoacylase (ASPA) result in the fatal brain
dysmyelinating disorder, Canavan disease. There is no
effective treatment. ASPA produces free acetate from the
concentrated brain metabolite, N-acetylaspartate (NAA).
Because acetyl coenzyme A is a key building block for
lipid synthesis, we postulated that the inability to catabolize
NAA leads to a brain acetate deficiency during a critical
period of CNS development, impairing myelination and
possibly other aspects of brain development. We tested the
hypothesis that acetate supplementation during postnatal
myelination would ameliorate the severe phenotype associ-
ated with ASPA deficiency using the tremor rat model of
Canavan disease. Glyceryltriacetate (GTA) was adminis-
tered orally to tremor rats starting 7 days after birth, and
was continued in food and water after weaning. Motor
function, myelin lipids, and brain vacuolation were ana-
lyzed in GTA-treated and untreated tremor rats. Significant
improvements were observed in motor performance and
myelin galactocerebroside content in tremor rats treated
with GTA. Further, brain vacuolation was modestly
reduced, and these reductions were positively correlated
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DOI 10.1007/s10545-010-9100-zwith improved motor performance. We also examined the
expression of the acetyl coenzyme A synthesizing enzyme
acetyl coenzyme A synthase 1 and found upregulation of
expression in tremor rats, with a return to near normal
expression levels in GTA-treated tremor rats. These results
confirm the critical role played by NAA-derived acetate in
brain myelination and development, and demonstrate the
potential usefulness of acetate therapy for the treatment of
Canavan disease.
Abbreviations
AceCS1 Acetyl coenzyme A synthase type 1
ASPA Aspartoacylase
GTA Glyceryltriacetate
NAA N-acetylaspartate
Introduction
Canavan disease is an autosomal genetic disorder that
results in progressive leukodystrophy, paralysis, and
death, usually between 3 and 10 years of age. Currently,
there is no effective treatment for this fatal disorder.
Canavan disease is caused by mutations in the gene that
codes for the enzyme aspartoacylase (ASPA; EC
3.5.1.15) (Matalon et al. 1988). ASPA deacetylates the
highly concentrated nervous system-specific molecule, N-
acetylaspartate (NAA). The primary metabolic effects of
mutations in the gene for ASPA in Canavan disease
patients are a lack of NAA deacetylation leading to
buildup of NAA in the brain (Kvittingen et al. 1986),
decreased brain acetate levels and impaired myelin lipid
synthesis (Madhavarao et al. 2005), and greatly increased
excretion of NAA in urine. Two hypotheses have been put
forward concerning the etiology of Canavan disease
(reviewed in Moffett et al. 2007), which suggest disparate
treatment strategies.
One treatment strategy is predicated on the hypothesis
that NAA is an osmolyte involved in the active regulation
of neuronal water balance (Baslow 1999). In this hypoth-
esis, the lack of ASPA activity leads to an inability to
control osmolarity in axons, resulting in damage to myelin
sheaths and a progressive leukodystrophy (Baslow 2003).
Treatment for Canavan disease under this hypothesis has
focused on ASPA gene transfer to reduce brain NAA levels
(Janson et al. 2002; Leone et al. 2000). To date, ASPA gene
transfer therapy has not proven successful in improving
motor functions. Based on findings that NAA-derived
acetate is responsible for as much as 1/3 of the lipid
synthesis that occurs during postnatal myelination, we have
proposed that metabolic therapy using acetate supplemen-
tation during postnatal myelination might be an effective
treatment for Canavan disease (Madhavarao et al. 2004,
2005). Glyceryltriacetate (GTA), the acetate triester of
glycerol, was used for acetate supplementation in the
current study because it is well tolerated when given orally
(Madhavarao et al. 2009) and intravenously (Bailey et al.
1991, 1992), and is distributed to the brain rapidly due to its
hydrophobic nature (Mathew et al. 2005).
The current studies examine the use of GTA as a
metabolic treatment for ASPA deficiency using the tremor
rat model of Canavan disease. These animals develop a
spongy degeneration of the brain, as is the case with ASPA
(-/-) knockout mice and Canavan disease patients. The
tremor rat model has been used previously for both gene
transfer therapy experiments (Klugmann et al. 2005;
McPhee et al. 2005) and myelin lipid analyses (Wang et
al. 2009). We bred homozygous, ASPA-deficient tremor
rats from heterozygous adults, and treated them with orally
administered GTA. Here, we report on the phenotypic
improvements in motor function, myelin galactocerebroside
content, and brain vacuolation observed in GTA-treated
tremor rats as compared with those who were untreated.
Both NAA-derived acetate and GTA-derived acetate must
be converted to acetyl coenzyme A before the acetate can
be utilized for metabolic reactions such as lipid synthesis.
We therefore examined acetyl coenzyme A synthase type 1
(AceCS1) expression in 18-day-old wild-type rats, and in
untreated and GTA-treated tremor rats to determine the
cellular localization of this enzyme during myelination and
in response to GTA treatment.
Materials and methods
Tremor rat breeding
All the procedures were performed in accordance with
guidelines of the National Institutes of Health and the
Institutional Animal Care and Use Committee. Pairs of
breeder heterozygote tremor rats were supplied by the
National Bio Resource Project for the Rat in Japan, Kyoto
University (Kyoto, Japan). ASPA-null tremor rats (tm/tm)
were bred from heterozygous adults (tm/+), and identified
tentatively based on their appearance at birth. Tremor rat
pups could be distinguished from wild-type pups based on
the presence of curled vibrissae. PCR analyses were used to
confirm the genotype of tremor rats. PCR was performed
on rat tail tissue digests (Direct PCR kit; Viagen Biotech,
Los Angeles, CA) using primers 5′-TTCAACAGAGGAAT
GGATACAGAAA and 5′- CACTCCATGCTTCCTTTT
CAACAGC (Kitada et al. 2000) at an annealing tempera-
ture of 55°C, and Mg
++ concentration of 1.5 mM using a
commercial kit (New England Biolabs, Ipswich, MA).
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ASPA immunohistochemistry was used to confirm the
ASPA-deficient phenotype of homozygous tremor rats.
The ASPA antibodies were generated against an 18 amino
acid sequence from human ASPA as previously described
(Hershfield et al. 2006). In addition, immunohistochemistry
was done with rabbit polyclonal antibodies to the enzyme
acetyl coenzyme A synthase-1 (AceCS1) in order to
determine if this enzyme was present in oligodendrocytes
during postnatal myelination, and if it was expressed in the
tremor rat brain. Rabbit polyclonal antibodies were generat-
edagainstpurified,recombinantAceCS1 protein(Hallowset
al. 2006), and have been described previously (Ariyannur et
al. 2010). Five wild-type Wistar rats, 3 untreated tremor
rats, and 2 GTA-treated tremor rats (Kyoto Wistar strain,
160–250 g, bred in our facility) were anesthetized with
pentobarbital (100 mg/kg) and perfused transcardially with
400 ml of 4% freshly depolymerized paraformaldehyde.
Two 18-day-old Sprague Dawley rats were anesthetized
with pentobarbital (100 mg/kg) and perfused transcardially
with 200 ml of 4% freshly depolymerized paraformalde-
hyde. Brains were removed and postfixed for 3–6hi n
paraformaldehyde before being passed through a series of
10, 20, and 30% sucrose solutions. Brains were sectioned at
a thickness of 20 μma t−17°C and tissue slices were
collected in PBS.
Avidin-biotin complex/peroxidase immunohistochem-
istry was done as previously described (Ariyannur et al.
2010; Madhavarao et al. 2004). Tissue sections were
incubated overnight with anti-ASPA antibodies at a
dilution of 1:30,000, or anti-AceCS1 antibodies at a
dilution of 1:5,000. Bound antibodies were visualized by
the avidin-biotin complex method with horseradish perox-
idase as the enzyme marker (Vectastain Elite; Vector Labs,
Burlingame, CA), and were developed with a Ni and Co
enhanced diaminobenzidene chromogen (Pierce Chemical,
Rockford, IL). Images were adjusted for brightness and
contrast using PC-based imaging software (Media Cyber-
netics, Silver Spring, MD, and Adobe Systems, San Jose,
CA).
SDS-PAGE and western blotting
SDS-PAGE and western blotting of brain proteins was done
as previously described (Hershfield et al. 2006). Adult
wild-type and tremor rats were deeply anesthetized prior to
sacrifice, and the brains were removed, frozen on dry ice,
and stored at −80°C until use. Tissue homogenates were
prepared with a Potter-Elvejham homogenizer in isolation
medium. Homogenates were centrifuged (16,000g, 10 min,
4°C) and the supernatants were used for SDS-PAGE.
Protein concentrations were determined by Bio-Rad’sD C
protein assay (Hercules, CA), and 60 µg of protein were
loaded per sample. Following electrophoresis, samples
were transferred to Immobilon-P PVDF membranes and
incubated overnight with the ASPA peptide antibody
(1:15,000 dilution) at 4°C. Membranes were washed in
PBS, and then incubated for 1 h with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody
at a dilution of 1:2,500. Membranes were washed and
developed with diaminobenzidine substrate.
GTA treatment of tremor rats
GTAwas given orally to tremor rat pups once in the morning
(9:00–10:00 am) and once in the evening (4:30–5:30 pm)
starting from day 7 after birth at a dose of 4.2 g/kg until day
14. The dose of GTA was increased to 5.8 g/kg on day
15 until the pups were weaned (22/23 days after birth).
After weaning, the pups received GTA in their rat food
( 7 . 5 %o fG T Ab yw e i g h t )a n dw a t e r( 5 %G T Ab y
weight). The untreated tremor rat pups were given normal
r a tf e e da n dw a t e ra f t e rw e a n i n gu pt oa p p r o x i m a t e l y
4m o n t h s .
Rotarod performance evaluation
Each Rotarod treadmill (Med Associates, Georgia, VT)
consisted of a motor-driven drum with constant speed or
accelerating speed modes of operation. The drum allows
each animal to maintain a suitable grip. The equipment
consisted of a metal frame of rotating rods (25.5 cm high
from the bench, 6.0 cm diameter). The cylinders were
connected to a variable speed reversible motor, allowing the
speed and direction of rotation of the cylinders to be
changed. Rats were tested using an accelerated Rotarod
protocol with progressively increasing speed from 2 to
20 rpm. Motor performance was monitored for 3 min per
trial. After the treated and untreated tremor rats reached
45 days of age, they were tested biweekly on the Rotarod
treadmill over the course of GTA treatment (up to
∼4 months). For each time point, 5 trials were conducted
for each rat and the average balance time in seconds was
recorded.
Locomotion evaluation
Locomotor activity was measured using an Acuscan animal
activity monitor with infrared photocell system (model
RXYZCM; Omnitech, Acuscan Electronics, Columbus,
OH), located in a dedicated room within the animal facility
as previously described (Elliott et al. 2004). Briefly,
animals were placed singly in a 40×40×30 (L×W×H)
cm clear Plexiglas arena and lid with multiple 3.5-cm-
diameter holes placed on top of the arena. One hour of
J Inherit Metab Dis (2010) 33:195–210 197activity was monitored, and data were automatically
gathered and transmitted to computer via an Omnitech
Model DCM-I-BBU Digiscan analyzer.
Statistical analyses of the Rotarod data and locomotion data
These studies were conducted over a 2.5-year period due to
the difficulties in breeding adequate numbers of tremor
mutant pups from heterozygote adults. As such, there were
fewer rats per group at the outset of the study. The mutant
rat pups from different litters were randomly assigned after
birth to treated and untreated groups in the two categories
of male and female tremor rats. This led to unequal and
variable group sizes that precluded using repeated measures
ANOVA to analyze the data. The average Rotarod balance
time (s) data failed the assumption of normality or equal
variance or both and therefore was analyzed by Kruskal-
Wallis ANOVA of the ranks. When the H statistic was
found to be significant the differences in ranks were
compared by the method of Dunn. Rotarod performance
was compared at different ages of the tremor rats (time
points) as well as the averages of all the time points over
the course of the study.
The data on locomotion parameters including horizontal
activity units (number of events), total distance moved (cm)
and move time (s) were also analyzed at different time
points. One-way ANOVA was performed directly on the
average values and the significant F statistic was followed
by a post-hoc test method (Holm-Sidak) for significance of
mean differences. All statistical analyses were performed
using either the SPSS package for statistical analyses
version 14.0 or Sigma Plot version 11.0. The results were
identical when an analysis was repeated by interchanging
the software.
Quantification of vacuolation
Rats were euthanized at the end of the study (∼110 days for
wild-type rats and ∼120 days for tremor rats). Animals were
anesthetized and the brain tissue fixed by transcardial
perfusion with buffered formalin. Formalin-fixed, paraffin-
embedded brain sections (∼7 micrometer) were stained with
hematoxylin and eosin for scoring of vacuolation. The
cerebellum/brain stem and spinal cord showed changes in
the vacuolation pattern in treated and untreated rats. A
random set of processed slides were drawn for analyses,
and they were scored for severity of vacuolation by a
board-certified veterinary pathologist blinded to the study.
The sections were scored 0 (no vacuolation), 1 (mild
vacuolation), 2 (moderate vacuolation), and 3 (severe
vacuolation), and the normalized score was computed and
expressed as a percentage as ½ sum ð of all the scoresÞ
= total of possible maximum scores ðÞ   » 100 ðÞ .
Regression analysis of severity of vacuolation and Rotarod
performance
The average Rotarod performance of the sampled rats
was compared individually against the score they
received for severity of vacuolation in the cerebellum/
brain stem and spinal cord and analyzed separately for
the two regions. A regression analysis was performed
(Sigma Plot version 11.0) to determine the degree of
correlation between the vacuolation scoring pattern and
Rotarod performance, and to determine if there was a
treatment effect.
Myelin preparation and TLC for myelin lipids
Rat brain myelin was isolated as previously described
(Madhavarao et al. 2005) using the procedure of Norton
and Poduslo (1973). Briefly, rat brains were homogenized
(10% w/v) using a polytron blender with isolation and re-
suspension buffer (50 mM Tris-HCl, 50 mM NaCl, 0.32 M
sucrose) and protease inhibitor cocktail according to the
manufacturer’s instructions (Sigma-Aldrich) and the myelin
was isolated by sucrose density gradient and centrifugation
(75,000g for 25 min). The myelin fraction was subjected to
hypo-osmotic shock, centrifuged (12,000g for 10 min) and
collected as a pellet. The pellet was suspended in 0.5 ml re-
suspension buffer (50 mM Tris-HCl, 50 mM NaCl, 0.32 M
sucrose). Myelin was extracted using 2:1 chloroform:
methanol and the myelin proteins were solubilized in
0.1 N NaOH for 3 days and protein content quantified
using a commercial kit (Bio-Rad).
Myelin lipids were separated by two-dimensional TLC
as previously described (Madhavarao et al. 2005)w i t ht h e
following adjustments. First dimension: solvent system 1
(diethyl ether: benzene: ethanol: acetic acid; 40:50:2:0.2
v/v) solvent front advanced 2/3rds plate height and dried.
Solvent system 2 (diethyl ether: hexane; 6:94 v/v) was
run the full plate height. Second dimension: solvent
system 1 (chloroform: methanol: ammonium hydroxide;
50:30:1 v/v) solvent front advanced to half the plate
height and dried. Solvent system 2 (chloroform: metha-
nol; 10:3 v/v) was run the full course of the second
dimension. The spots were developed by spraying with
bromophenol blue dye (0.05% in 50% methanol solution)
with slight heating. Spot intensities were quantified from
digital photographs using PC-based imaging software
(Adobe Systems). Individual lipid spot intensities were
expressed as a fraction of the total lipid intensity value
obtained by summation of values for all discernible lipid
spots in a single TLC run. The individual lipid spot
values were then normalized to myelin protein concen-
trations as previously described (Madhavarao et al.
2005).
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Genotyping
Tremor rat genotypes were confirmed by PCR. The hetero-
zygotes(tm/+) andtremor rats(tm/tm) yieldeda 179-bpPCR
product which is absent in wild-type rats (+/+). Molecular
genotyping is necessary for the identification of the hetero-
zygotes used to breed the mutant tremor rats.
ASPA immunohistochemistry and western blotting
ASPA immunohistochemistry was used to confirm the
ASPA-null phenotype in tremor rats. Figure 1 shows brain
sections from wild-type and tremor rats stained with an
antibody against human ASPA (Hershfield et al. 2006).
ASPA expression was strong in oligodendrocytes in wild-
type rats (Fig. 1a), whereas expression was undetectable in
tremor rats (Fig. 1b). Western blots showed an approxi-
mately 37-kD protein band in brain extracts from normal
Kyoto Wistar rats which was absent in brain extracts from
tremor rats (inset in Fig. 1b). These results confirmed the
ASPA-null genotype in tremor rats and demonstrated the
total lack of protein expression in homozygous (tm/tm) rats.
Rotarod treadmill performance
An accelerated Rotarod treadmill test was used to evaluate
coordination and motor performance in GTA-treated and
untreated tremor rats. GTA treatment significantly im-
proved tremor rat performance on the Rotarod treadmill
over the entire course of the trials (Fig. 2). Treated tremor
rats improved their performance over time, whereas
untreated tremor rats did not. GTA-treated female tremor
rats (Fig. 2a) showed a greater improvement in Rotarod
performance than males (Fig. 2b). GTA treatment did not
affect the performance of wild-type rats (data not given).
Treated female tremor rat performance on the Rotarod
reached approximately 50% of the values observed for
wild-type rats (average balance time of 157±15 seconds for
wild-type rats, 76±11 s for GTA-treated female tremor rats,
and 27±5 s for untreated female tremor rats). Treadmill
Fig. 2 Longitudinal study of Rotarod performance in GTA-treated
and untreated tremor rats. The differences between the GTA-treated
and untreated groups were significant by ANOVA (p<0.001) and
significant by post-hoc analysis with Tukey’s HSD (p<0.05). Rotarod
performance of female tremor rats is shown in (a), performance of
male tremor rats is shown in (b). Animal numbers per test session
were variable; n=11–16 (av. 12) for treated tremor females (TR-F), 4–
18 (av. 12) for untreated tremor females (UT-F), 9–14 (av. 10) for
treated tremor males (TR-M), and 7–16 (av. 11) for untreated tremor
males (UT-M). See Table 2 for statistical analyses of individual testing
sessions
Fig. 1 Immunohistochemistry and western blots were used to confirm
the ASPA null phenotype in tremor rats. ASPA expression is shown
for wild-type (a), and tremor rats (b). ASPA-immunoreactive cells in
(a) are predominantly oligodendrocytes in the internal capsule, and
surrounding forebrain fiber tracts. Immunoreactivity is absent in brain
tissue from tremor rats (b). Inset in (b) is a western blot of brain
protein extracts from wild-type (WT) and tremor rats (Tr) showing a
single immunoreactive band at approximately 37 kD in the wild-type
rat extract that is absent in the tremor rat extract. VL Lateral ventricle,
int internal capsule, CP caudate putamen
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mately three times greater than untreated females, and for
males, the values were approximately doubled. See Table 1
for statistical analysis of the Rotarod data.
Locomotion analysis
ASPA deficiency severely impairs motor function and
reduces spontaneous ambulatory and exploratory activity.
To assess the effects of GTA treatment on locomotion and
exploratory activity, we analyzed animal movements,
including horizontal movements, distance moved, and
move time using an Acuscan automated activity chamber.
Animals were tested multiple times starting at around
40 days of age, but statistically significant differences in
locomotion were not observed until animals were approx-
imately 70 days old. Statistically significant differences
were observed during the last 4 testing sessions at 70, 85,
98, and 110 days of age. GTA treatment significantly
increased activity levels in male and female tremor rats,
with greater improvements tending to occur later in the
study. Figure 3 shows the comparison of average values of
open-field parameters for the treated and untreated tremor
rats at 98 and 110 days of age. Treated female tremor rats
exhibited the most significant differences in locomotion
from untreated females at 98 days, whereas treated male
tremor rats showed the most significant improvements at
110 days. See Table 2 for statistical analysis of the
locomotion data.
Vacuolation scoring and regression analysis with Rotarod
data
Severe vacuolation of thalamus, hypothalamus, brain stem,
and spinal cord is a characteristic feature of Canavan disease
pathology (Adachi et al. 1973). It is also observed in the
animal models of the disease, including tremor rats. To
determine if GTA treatment had positive effects in reducing
brain vacuolation, a veterinary pathologist who was blinded
to the treatment groups scored the vacuolation in cerebellum/
brain stem and spinal cord from a randomly selected group of
the animals used for the Rotarod and locomotion analyses.
Figure 4 shows regression analyses between the vacuolation
scoring and performance on the Rotarod balance test. The
regression plot for the vacuolation in cerebellum/brain stem
versus Rotarod data is given in Fig. 4a, whereas the plot for
vacuolation in the spinal cord versus Rotarod data is given in
Fig. 4b. The decreased vacuolation in cerebellum/brain stem
and spinal cord was positively correlated with the motor
improvements observed using the Rotarod treadmill. The
correlation coefficients (r) determined for plots (a) and (b)
were 0.72 and 0.61, and were found to be significant with
p values of 0.01 and 0.04 for the F values of 13.15 and 7.79
(by ANOVA), respectively.
Table 1 Statistical analysis of Rotarod balance time (s) at different ages and the average performance over the entire study of the GTA-treated and
untreated female and male tremor rats
Average age of the groups ANOVA statistic Groups compared Significance (p value) Test method
37 days Unadjusted TR-F vs UT-F NS Dunn
H=14.94 (p=0.002) TR-M vs UT-M NS
53 days Unadjusted TR-F vs UT-F p<0.05 Dunn
H=23.17 (p<0.001) TR-M vs UT-M NS
68 days Unadjusted TR-F vs UT-F p<0.05 Dunn
H=24.93 (p<0.001) TR-M vs UT-M NS
83 days Unadjusted TR-F vs UT-F NS Dunn
H=17.74 (p<0.001) TR-M vs UT-M p<0.05
97 days Unadjusted TR-F vs UT-F NS Dunn
H=15.74 (p=0.001) TR-M vs UT-M p<0.05
111 days Unadjusted TR-F vs UT-F p<0.05 Dunn
H=16.60 (p<0.001) TR-M vs UT-M p<0.05
133 days Unadjusted TR-F vs UT-F NS Dunn
H=14.34 (p=0.002) TR-M vs UT-M p< 0.05
Over the course of study Unadjusted TR-F vs UT-F p< 0.05 Dunn
H=25.98 (p<0.001) TR-M vs UT-M p< 0.05
Average Rotarod balance times of treated female (TR-F), untreated female (UT-F), treated male (TR-M), and untreated male (UT-M) tremor rats
were included for analysis. One-way ANOVA on the ranks of the average Rotarod balance times was performed by Kruskal-Wallis method since
the data failed either the test of normality or the test of equal variance or both. The H statistic was verified for significance. The differences
between the median values were tested to rule out chance by Dunn’s method. p values greater than 0.1 are indicated as NS (not significant)
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Myelin lipid content in treated and untreated tremor rats
was analyzed by 2-dimensional thin layer chromatography
(2D TLC). Table 3 presents the intensity values for the lipid
spots on the 2D TLC plates for the treated and untreated
female tremor rats. Changes in lipid content in the treated
male tremor rats did not reach statistical significance (data
not shown). Galactocerebroside levels in the female GTA-
treated tremor rats were increased by approximately 20%,
which did reach significance (p≤0.05, n=4–5). Galactocer-
ebrosides are one of the critical myelin-associated lipids
that have been found to be specifically reduced in Canavan
disease (Madhavarao et al. 2005;W a n ge ta l .2009).
Improvements were observed in a number of other myelin
lipids including sphingomyelin, phosphatidylethanolamine,
phosphatidylglycerol, sulfatides, ceramides containing α-
hydroxy fatty acids, and cholesterol, but due to inter-animal
variability, these changes were not large enough to reach
statistical significance.
AceCS1 immunoreactivity in 18-day-old and adult
wild-type rats and adult tremor rats
Free acetate derived from the hydrolysis of GTA in the
brain, as well the free acetate derived by the ASPA-
Fig. 3 Average values of total
horizontal activity, distance
moved (cm) and move time (s)
were recorded for the treated
and untreated tremor rats at 4
time points at approximately 70,
85, 98, and 110 (±3) days of
age. The data were collected for
1 h in an open-field apparatus.
Data are shown for testing at 98
and 110 days of age; the testing
days when treated female and
treated male tremor rats showed
the greatest improvements re-
spectively. The number of rats in
the different groups tested were
as follows: treated female (Tr
Fem, 12); untreated female (Ut
Fem, 15); treated male (Tr Male,
12), and untreated male (Ut
Male, 14)
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Parameter Average age of
groups
a
Groups
compared
ANOVA statistic
b Significance of difference between
groups (p value)
c
Test
method
Total horizontal activity
(movements)
70 days TR-F vs
UT-F
F=7.21 (p≤0.001) NS Holm-
Sidak
TR-M vs
UT-M
0.04 (unadjusted)
85 days TR-F vs
UT-F
F=4.98 (p=0.004) 0.025 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.053 (unadjusted)
98 days TR-F vs
UT-F
F=10.04 (p≤0.001) 0.001 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.08 (unadjusted)
110 days TR-F vs
UT-F
F=7.19 (p≤0.001) 0.012 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.017 (unadjusted)
Total distance moved (cm) 70 days TR-F vs
UT-F
Unadjusted H=23.5
(p≤0.001)
NS Dunn
TR-M vs
UT-M
NS
85 days TR-F vs
UT-F
Unadjusted H=11.3
(p≤0.01)
NS Dunn
TR-M vs
UT-M
NS
98 days TR-F vs
UT-F
F=10.26 (p≤0.001) 0.002 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
NS
110 days TR-F vs
UT-F
F=6.7 (p=0.001) 0.097 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.028 (unadjusted)
Total move time (sec) 70 days TR-F vs
UT-F
F=10.69 (p≤0.001) NS Holm-
Sidak
TR-M vs
UT-M
0.01 (unadjusted)
85 days TR-F vs
UT-F
F=5.6 (p=0.002) 0.01 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.06 (unadjusted)
98 days TR-F vs
UT-F
F=7.7 (p≤0.001) 0.005 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.04 (unadjusted)
110 days TR-F vs
UT-F
F=6.63 (p=0.001) 0.084 (unadjusted) Holm-
Sidak
TR-M vs
UT-M
0.012 (unadjusted)
Statistics are given for the locomotion data including total horizontal activity movements, total distance moved, and total move time over the
course of a 1-h observation period on 4 different testing sessions (∼70, 85, 98, and 110 days of age)
aData were collected starting from ∼40-day-old tremor rats but statistically discernible differences between the treated and untreated groups were not found
until the tremor rats reached around 70 days of age
bOne-way ANOVAwas performed on the mean values of treated female (TR-F), untreated female (UT-F), treated male (TR-M) and untreated male (UT-M)
tremor rats and the F statistic was verified for significance when the data conformed to assumptions of normality and equal variance. When the data did not
conform to the either or both of the assumptions, one-way ANOVA on the ranks was performed by Kruskal-Wallis method and the H statistic was verified
for significance
cp values greater than 0.1 are indicated as NS (not significant)
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coenzyme A before it can be further metabolized. We
hypothesized that the most likely candidate enzyme for this
metabolic reaction is acetyl coenzyme A synthase-1
(AceCS1) (Moffett et al. 2007), which converts free acetate
and coenzyme A to acetyl coenzyme A for lipid synthesis,
among other functions. In order to begin addressing this
question, we employed antibodies to AceCS1 (Ariyannur et
al. 2010) to determine if oligodendrocytes express this
enzyme during the peak period of postnatal myelination (18
days of age in rats). We found that AceCS1 is expressed
predominantly in cell nuclei throughout the brain (Fig. 5).
Expression was strong in the nucleus and light to moderate
in the cytoplasm of many oligodendrocytes in 18-day-old
wild-type rats. Whereas the cytoplasmic localization of
AceCS1 in oligodendrocytes is consistent with a role in
myelin lipid synthesis, the prominent nuclear localization of
AceCS1 in oligodendrocytes and other cell types in the
brain may have implications for gene regulation and
cellular differentiation and maturation (Copray et al. 2009;
Kumar et al. 2009).
AceCS1 expression was upregulated in adult tremor rats
as compared with controls (Figs. 6 and 7). AceCS1 was
expressed moderately to strongly in some cellular nuclei in
adult control rats, including neuronal and glial cell nuclei
(Figs. 6a, b and 7a). In tremor rats, AceCS1 expression was
substantially increased relative to control animals (Figs. 6c,
d and 7b). GTA-treatment of tremor rats reduced AceCS1
expression relative to untreated tremor rats and returned
expression levels closer to those observed in control rats
(Figs. 6e, f and 7c). In brain areas where severe vacuolation
was observed in tremor rats, GTA treatment modestly
reduced the degree of vacuolation. The lateral hypothala-
mus is one forebrain area that exhibits substantial vacuo-
lation in tremor rats (Fig. 8). In wild-type control rats,
AceCS1 expression was present in scattered cell nuclei
throughout this region (Fig. 8a). In untreated tremor rats,
AceCS1 expression was upregulated, and extensive vacu-
olation was observed in the lateral hypothalamus (Fig. 8b).
Fig. 4 Regression analysis of the severity of vacuolation in the
cerebellum/brain stem (a) and spinal cord (b) with the average
Rotarod performance of individual rats (n=7). The randomly selected
sample consisted of 2 untreated female tremor rats, 2 treated female
tremor rats, one untreated male tremor rat, one treated male tremor rat,
and one untreated female wild-type rat of the same strain. The
correlation coefficients, r, determined for plots (a) and (b) were 0.72
and 0.61, and were found to be significant with p values of 0.01 and
0.04 for the F values of 13.15 and 7.79 (by ANOVA), respectively.
The vacuolation scores were determined by a veterinary pathologist
blinded to the study. The values for the treated tremor rats tended to
fall intermediate between values found for the untreated tremor rats
and the wild-type rat
Table 3 Average values of myelin lipids (spot intensities) in female
rats
Wild-type Treated Untreated
Mean SEM Mean SEM Mean SEM
PA 18,534±4,501 11,736±1,390 13,258±2,078
PC 26,196±8,001 35,743±3,419 27,925±3,965
SM 32,245±9,809 25,842±3,557 18,627±3,703
PI 47,320±7,484 27,724±2,914 23,511±2,128
PE 46,863±13,763 59,662±14,832 36,906±12,843
PG 48,378±16,358 42,316±8,548 35,176±7,153
Sulfatides 37,840±7,480 28,825±4,908 25,761±5,142
GC* 26,373±6,260 18,157±3,000 15,093±2,943
HFAC 12,753±2,272 9,268±1,629 7,278±1,640
Cholesterol 51,278±4,719 29,553±5,625 25,218±4,226
Mean values of myelin lipid levels (n=4–5 for each value) from wild-
type female rats and GTA-treated and untreated female tremor rats
were compared by paired t test. Many lipid values were increased with
GTA treatment, but did not reach the p<0.05 significance level due to
animal to animal variability. Galactocerebroside (GC*) levels were
significantly different between the treated and untreated female tremor
rats (p<0.05). PA Phosphatidic acid, PC phosphatidylcholine, SM
sphingomyelin, PI phosphatidylinositol, PE phosphatidylethanol-
amine, PG phosphatidylglycerol, sulfatides, HFAC ceramides contain-
ing α-hydroxy fatty acids
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reduced to near control levels, and the degree of vacuola-
tion was modestly reduced (Fig. 8c).
Discussion
Once the genetic basis of Canavan disease was discovered
(Matalon et al. 1988), the primary question centered on
whether the etiology involved toxic buildup of NAA, or
impaired brain metabolism associated with the inability to
catabolize NAA. Under the assumption that excess NAA
was toxic, ASPA gene transfer appeared to be the most
logical method of reversing the effects of ASPA deficiency
in Canavan patients. This method has been attempted in
animal models of Canavan disease (Klugmann et al. 2005;
McPhee et al. 2005) and in a group of over 20 children with
the disease (Janson et al. 2002; Leone et al. 2000). No
positive long-term outcomes on motor function have been
reported using ASPA gene transfer to ameliorate ASPA
deficiency. Taking the approach that failure to metabolize
NAA leads to a brain acetate deficiency during postnatal
development and myelination, the current investigation is
the first in a series of ongoing studies into the potential use
of GTA supplementation for the treatment of Canavan
disease.
We found that GTA is effective in significantly reducing
the severe phenotypic sequelae of ASPA enzymatic
deficiency in the tremor rat model of Canavan disease over
the course of a 4-month study. In tremor rats treated with
GTA, motor performance was significantly improved, with
the greatest improvements occurring later in the longitudi-
nal study (Fig. 2). Further, galactocerebroside content in
myelin was modestly (∼20%) but significantly increased
(see Table 3). Galactocerebrosides are one of the function-
ally important classes of myelin-associated lipids that are
Fig. 5 AceCS1-immunoreactivity
in oligodendrocytes in white matter
from an 18-day-old wild-type
rat. The fimbria of the hippo-
c a m p u si ss h o w ni n( a)a n d
(b), demonstrating numerous
immunoreactive oligodendro-
cytes. AceCS1 expression in
the corpus callosum of an
18-day-old rat is shown in (c)
and (d). Immunoreactive oligo-
dendrocytes in the internal
capsule are shown in (e)a n d
(f). AceCS1 expression was
generally stronger in oligoden-
drocyte nuclei than in their
cytoplasm. CA3 Pyramidal cell
l a y e ro fh i p p o c a m p a lA m m o n ’s
horn CA3 region, cc corpus
callosum, CP caudate/putamen,
fim fimbria of the hippocampus,
ic internal capsule, LV lateral
ventricle, st stria terminalis.
Bar (in f): 120 µm (a,c,e),
30 µm (b,d,f)
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ASPA-deficient animal models (Madhavarao et al. 2005;
Wang et al. 2009). Additionally, vacuolation in the brain
and spinal cord was found to be modestly reduced with
GTA treatment (Fig. 8), and the decreased vacuolation was
positively correlated with improved performance on the
Rotarod treadmill test (Fig. 4). These results support the
acetate deficiency hypothesis of Canavan disease. Ongoing
studies with ASPA -/- knockout mice (Matalon et al. 2000)
are underway to confirm these results in another model
system.
In previous studies, we found that administration of
GTA to mice at a dose of 5.8 g/kg increases acetate levels
in the brain over 15-fold within an hour, and the levels
remain elevated for several hours after administration
(Mathew et al. 2005). Further, short and long term toxicity
studies have shown that GTA is well tolerated (Bailey et al.
1991, 1992; Madhavarao et al. 2009). GTA does not require
specific transport mechanisms to enter the cytoplasm of
cells. Once internalized in cells, GTA is broken down to
acetate and glycerol by the action of non-specific esterases.
These factors make GTA especially useful for acetate
delivery to the brain. Plasma acetate derived from GTA
breakdown in the intestine, liver and bloodstream can also
be taken up by the brain.
The current GTA treatment partially reversed the severe
motor dysfunction of tremor rats. Rotarod treadmill motor
performance scores in treated female tremor rats reached
approximately 50% of those achieved by age-matched
wild-type rats. This compares favorably with performance
scores for untreated female tremor rats, which were only
about 15% of those seen with wild-type rats. So, despite
significant improvement in motor performance, the treated
rats still had substantial leeway for further improvement.
Additionally, GTA treatment improved the spongiform
vacuolation in brain only partially, and substantial vacuo-
Fig. 6 AceCS1-immunoreactivity
comparison between adult wild,
type and GTA treated and un-
treated tremor rats: low mag-
nification images (left column),
higher magnification images
(right column). AceCS1 immu-
noreactivity in the cortex of an
adult control rat (a,b)s h o w s
expression predominantly in
cell nuclei in all layers of
cortex. In a representative un-
treated adult tremor rat (c,d),
AceCS1 expression was mod-
erately upregulated, including
in oligodendrocytes in the
corpus callosum (cc). In a rep-
resentative adult GTA-treated
tremor rat (e,f), AceCS1 ex-
pression was reduced relative to
untreated tremor rats, and was
similar to the expression levels
in control animals. Bar (in f):
300 µm (a,c,e), 120 µm (b,d,f)
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Finally, myelin lipid content was improved modestly but
did not reach wild-type levels, indicating that further
optimization of the treatment regimen is necessary to
increase effectiveness. Male and female tremor rats per-
formed differently in treadmill balance time and locomotion
testing. Female tremor rats consistently performed better
than males. Additionally, female tremor rats responded
more favorably to GTA treatment. The reason for the poor
performance of the males is uncertain, but may relate to the
genetic deletion in tremor rats, which spans three genes in
addition to the gene for ASPA (Kitada et al. 2000).
Several possible improvements could be made to the
current GTA supplementation regimen that may provide
increased efficacy. GTA was only administered twice daily
during the treatment period, and it may be found that
increasing the frequency of administration provides greater
recovery of function. In addition, GTA was administered in
water, whereas it is likely that administration in a complete
infant formula would provide increased efficacy due to
Fig. 8 AceCS1 expression and vacuole reduction in the lateral
hypothalamus with GTA treatment. AceCS1-immunoreactivity in an
adult wild-type rat (control) is shown in (a), with the supraoptic
nucleus denoted by the arrow. The lateral hypothalamus of an adult
tremor rat is shown in (b), exhibiting extensive vacuolation through-
out the area, and upregulation of AceCS1 expression. The lateral
hypothalamus of a GTA-treated adult tremor rat is shown in (c), with
reduced AceCS1 expression and reduced vacuolation as compared
with the untreated tremor rat. Bar 300 µm
Fig. 7 AceCS1 expression in layer V of cortex. In wild-type adult
rats, AceCS1 was expressed predominantly in scattered cell nuclei in
layer V of cortex (a). In adult tremor rats, the number of
immunoreactive cell nuclei in layer V was increased, and tended to
occur in clusters not seen in wild-type rats (b). In GTA-treated tremor
rats, the number of AceCS1 immunoreactive cell nuclei was reduced
relative to untreated tremor rats, and tended to be more scattered as in
the case of wild-type rats (c). Bar 60 µm
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treated for the first postnatal week due to the difficulty in
administering GTA orally to such young rats. It may be
possible to increase acetate delivery to prenatal tremor pups
and newborns by administering high levels of GTA to the
pregnant and nursing maternal rats. Because esterase
activity is high in gut and liver, it may be possible to
increase acetate delivery to the brain by combining GTA
with mild esterase inhibitors, such as the flavenoids found
in grapefruit juice (Li et al. 2007). Future studies comparing
intravenous administration of GTA to oral administration
will be important to determine if efficacy can be improved
by bypassing the digestive system.
The connection between NAA metabolism and lipid
synthesis in the brain was first noted in the 1960s. D’Adamo
and colleagues found that the acetate moiety of NAA is
incorporated into brain lipids, and proposed that NAA acts to
provideacetateforbrainlipidsynthesis(D’Adamoetal.1968;
D’Adamo and Yatsu 1966). Injecting carbon-14 and tritium-
labeled NAA into the brains of developing and adult rats,
they found that the acetate moiety was readily incorporated
into brain lipids during postnatal myelination. Approximate-
ly 1/3 of the carbon incorporated into lipids during
myelination was derived from the acetate group of NAA.
This finding is consistent with the recent findings from our
laboratory and the Ledeen laboratory that lipid synthesis is
reduced by about 1/3 in the brains of developing ASPA -/-
mice (Madhavarao et al. 2005) and tremor rats (Wang et al.
2009).
The present studies confirm earlier investigations indi-
cating a role for NAA as an acetyl source in brain lipid
synthesis, and show that NAA is likely to serve multiple
developmental and neurochemical roles in the nervous
system. We propose that the high concentration of NAA is
a nervous system-specific mechanism for storing and
transporting acetate to be used for acetyl coenzyme A
synthesis, and subsequent acetylation reactions critical for
brain development and function. A number of studies have
indicated that production of NAA in neuronal mitochondria
is somehow linked to energy metabolism in the brain (Patel
and Clark 1979), and this role could involve the use of
NAA as a storage and transport form of acetate. Impor-
tantly, NAA is probably a major source of acetate that is
transported from the site of synthesis in neurons to the site
of catalysis in oligodendrocytes where the free acetate can
be reconverted to acetyl coenzyme A for lipid synthesis
(Patel and Clark 1980) and protein acetylation reactions.
This would allow neurons to regulate the rate at which
acetate is supplied to their ensheathing oligodendrocytes.
The ASPA deficiency in the mouse knock-out model of
Canavan disease (Aspa -/- mice) results in an 80% reduction
in total brain acetate levels, as well as significant decreases
in the levels of certain polar and non-polar lipids including
cerebrosides during the period of postnatal myelination
(Madhavarao et al. 2005). The decrease in brain lipid content
has been verified in the tremor rat model of Canavan disease
(Wang et al. 2009), and in the Nur7 ASPA-deficient mouse
(Traka et al., 2008). However, further work with the Nur7
mouse suggested that disrupted myelin synthesis was not the
only pathogenic mechanism involved in the etiology of the
spongy degeneration associated with Canavan disease.
Specifically, Nur7 ASPA-deficient mice were generated that
were heterozygous for a null allele of the galactolipid-
synthesizing enzyme UDP-galactose:ceramide galactosyl-
transferase (Cgt), which further reduced brain cerebroside
content. Despite this further reduction in brain cerebroside
content, the mice were not more severely affected than those
harboring only homozygous Nur7 mutations in the Aspa
gene.
These findings implicate other potential mechanisms inthe
pathophysiology of ASPA deficiency in addition to defective
myelin synthesis. One aspect of the neuropathologies associ-
ated with ASPA deficiency that does not comport directly
with disrupted myelination is the substantial brain and spinal
cord vacuolation observed in gray matter, and sparing of
many white matter areas (Surendran et al. 2005; Traka et al.
2008). The vacuolation appears between postnatal days 14
and 21 in the Nur7 ASPA-deficient mouse, which coincides
with the peak of postnatal myelination. We have also
observed vacuolation in many gray matter areas and sparing
of specific white matter tracts in the adult tremor rat brain
(unpublished observations). Recent studies on oligodendro-
cyte maturation have highlighted the important role of
histone acetylation and deacetylation in the epigenetic
control of cellular differentiation from oligodendrocyte
precursor cells to mature oligodendrocytes (Copray et al.
2009; MacDonald and Roskams 2009;Y ee ta l .2009).
Because neurons transfer NAA to oligodendrocytes (Chak-
raborty et al. 2001), and oligodendrocytes strongly express
ASPA (Klugmann et al. 2003;M a d h a v a r a oe ta l .2004), it is
likely that NAA-derived acetate is an important source of
acetyl coenzyme A in oligodendrocytes for histone acetyla-
tion reactions that regulate chromatin structure and gene
transcription. The finding that ASPA is expressed in the
nuclei of oligodendrocytes, as well as in their cytoplasm
(Hershfield et al. 2006), is consistent with this role for NAA-
derived acetate. The dramatic reduction in acetate availabil-
ity in oligodendrocytes resulting from ASPA deficiency
could impact histone acetyltransferase reactions required for
epigenetic gene regulation. The resultant disruption of
oligodendrocyte differentiation would explain the observed
loss of mature oligodendrocytes in the cerebellum and
brainstem of Nur7 ASPA-deficient mice (Traka et al. 2008).
InorderforfreeacetatederivedfromNAAhydrolysistobe
utilized, it must be enzymatically converted to acetyl
coenzyme A. We found that acetyl coenzyme A synthase-1
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is present in the nuclei and cytoplasm of many oligoden-
drocytes in 18-day-old rats (Fig. 5). Further, AceCS1 protein
expression was upregulated in neurons and oligodendrocytes
in adult tremor rats as compared with wild-type controls
(Figs. 6 and 7). Expression of AceCS1 in GTA-treated
tremor rats was reduced relative to untreated tremor rats and
was returned to near wild-type levels. AceCS1 is known to
be involved in lipid synthesis (Luong et al. 2000) and has
recently been shown to be involved in histone acetylation
reactions necessary for cell differentiation (Wellen et al.
2009). The reduced substrate availability for AceCS1 could
negatively impact histone acetylation critical for proper
oligodendrocyte maturation (Copray et al. 2009;K u m a re t
al. 2009). It seems likely that ASPA deficiency leads to
improper regulation of histone acetylation in developing
oligodendrocytes, preventing normal differentiation and
leading to oligodendrocyte cell death, dysmyelination,
neuronal injury, and inflammation, possibly contributing to
vacuole formation. It is noteworthy that GTA treatment also
modestly reduced vacuole formation (see Fig. 8). One
important conclusion that can be drawn from these observa-
tions is that NAA-derived acetate is not only involved in
brain myelination but it may also be involved in gene
regulation associated with cellular differentiation and brain
development.
Another possible mechanism linking reduced acetyl
coenzymeAavailabilityandtheneuropathologiesinCanavan
disease involves posttranslational acetylation of proteins in
the endoplasmic reticulum, particularly in oligodendrocytes.
Cells which have active protein secretory pathways through
the endoplasmic reticulum, such as oligodendrocytes, are
sensitive to disorders of protein mis-folding. Acetylation and
deacetylation of nascent polypeptide chains in the endoplas-
mic reticulum secretory pathway of cells is required for
stabilization and correct folding (Costantini et al. 2007;
Spange et al. 2009). Acetyl coenzyme A is required for the
acetyltransferase reactions involved in acetylation at lysine
sites on newly synthesized proteins. The substantial drop in
brain acetate levels that occur in ASPA deficiency could
have a negative impact on protein folding and stabilization,
thus targeting proteins for endoplasmic reticulum associated
degradation (ERAD). In the ASPA knockout mouse, a
severe loss of myelin basic protein and PLP/DM20
proteolipid proteins has been observed, combined with a
decrease in myelinated fibers and perinuclear retention of
myelin protein staining. These are clear indicators of an
impairment in protein trafficking in oligodendrocytes
(Kumar et al. 2009). Oligodendrocytes are highly susceptible
to endoplasmic reticulum stress (ERS) associated with
disruptions in protein synthesis and trafficking (Lin and
Popko 2009). It is likely that the dramatic drop in NAA-
derived acetate in Canavan disease has a negative impact on
the protein secretory pathway in oligodendrocytes. Because
all of the potential pathogenic mechanisms involve reduc-
tions in acetate availability associated with the inability to
deacetylate NAA, it is possible that GTA administration may
provide needed substrate for acetyl coenzyme A synthesis
required for all three cellular functions; fatty acid synthesis,
nuclear histone acetylation, and endoplasmic reticulum
protein acetylation.
In conclusion, the acetate precursor GTA improved motor
performance and increased myelin galactocerebroside content
in the tremor rat model of Canavan disease, without overt
toxicity. GTA treatment also decreased brain vacuolation, and
the improvements in motor performance were positively
correlated with the reduced vacuolation. Additionally, GTA
treatment returned the elevated AceCS1 expression levels in
tremor rats to near control levels. None of the pathological
consequences of ASPA deficiency were completely reversed
by GTA administration, indicating that additional investiga-
tions and modifications to the treatment regimen will be
necessary to further improve long-term outcomes. Nonethe-
less, acetate supplementation is a safe and promising
treatment strategy for Canavan disease that is inexpensive
and easyto administer. GTA-based acetate supplementation is
a unique method for addressing dysmyelination in Canavan
disease in particular, and possibly other disorders of myelina-
tion, or brain injury (Arun et al. 2010). Finally, the important
role of NAA-derived acetate in brain development and
myelination is further confirmed. Additional research will be
required to determine the role of compromised nuclear
histone acetylation and endoplasmic reticulum protein
acetylation in the etiology of Canavan disease.
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